National Institute for Health and Care Excellence

Ulcerative colitis: management

# NICE guideline CG166 – consultation on research recommendations

Stakeholder consultation comments form

Please email your completed form to [UC\_CrohnsUpdate@nice.org.uk](mailto:UC_CrohnsUpdate@nice.org.uk)

The consultation period closes at 5 pm on 18/01/2019

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in reviewing NICE guidelines.

If you wish to draw our attention to published studies, please supply the full reference.

|  |  |
| --- | --- |
| Stakeholder details | |
| NICE is unable to accept comments from non-registered organisations.  If you wish your comments to be considered please register via the [NICE website](http://www.nice.org.uk/get-involved/stakeholder-registration) or contact the [registered stakeholder organisation](https://www.nice.org.uk/guidance/gid-ng10073/documents/stakeholder-list) that most closely represents your interests and pass your comments to them. | |
| Stakeholder organisation |  |
| Name of commentator |  |
| Should this research recommendation stand?  What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction of remission for people with moderate ulcerative colitis? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone plus an aminosalicylate for induction of remission for people with moderate ulcerative colitis? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What is the clinical and cost effectiveness of regular maintenance treatment compared with no regular treatment (but rapid standard treatment if a relapse occurs) in specific populations with mild to moderate ulcerative colitis? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  To develop and validate a risk tool that predicts the likelihood of needing surgery for adults admitted to hospital with acute severe ulcerative colitis. | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  In children and young people with ulcerative colitis receiving steroid treatment, what are the clinical benefits of routine monitoring of bone density, what tests should be done and how frequently? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  A registry to collect data to answer ‘What are the potential harms or benefits of drug treatments in pregnant women with ulcerative colitis?’ | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What are the information needs of people with ulcerative colitis when they are considering surgery? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What is the clinical and cost effectiveness of sulphasalazine compared to high-dose branded mesalazine for induction of remission for people with mild moderate ulcerative colitis? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What is the validity, reliability and accuracy of available adult risk tools as a predictor for the need for surgery in people admitted into hospital with acute severe ulcerative colitis? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What is the validity, reliability and accuracy of the paediatric ulcerative colitis activity index (PUCAI) as a predictor for surgery for children and young people admitted to hospital with acute severe colitis? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  In people with mild to moderate ulcerative colitis, what are the best second-line treatment strategies for induction of remission after people have failed to respond to ASA mono or combination therapies? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  In people with subacute ulcerative colitis, what are the best second-line treatment strategies for induction of remission after people have failed to respond to oral prednisolone? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  In people with mild to moderate ulcerative colitis, what are the best strategies for the induction of remission after people have failed to respond to tacrolimus? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  Establish a national registry to identify the incidence of growth failure and/or pubertal delay in ulcerative colitis and the relationship with treatment (to record treatment [steroids, ASA, immunomodulators] and growth [z scores]). | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.